5th Annual Biopharmaceutical Research & Development Symposium
Dates: September 5-6, 2018
Registration Deadline and abstract submission: August 10, 2018
Michael F. Sorrell Center for Health Science Education
Truhlsen Events Center, 1st floor
619 South 42nd Street
Surgery, radiation, chemo or their combinations are commonly used for cancer therapy. However, due to its late-stage detection, surgery-based treatments are limited. On the other hand, radiation and chemotherapy often fails due to higher cancer relapse rates. Conventional therapies typically kill cancer cells with severe side effects, however; immunotherapies boost the function of the host’s immune system to target, fight, and eradicate cancer cells without destroying healthy cells by mimicking the patient’s immune system. The cells of innate and adaptive immune systems are the essential components of mammalian defense system, which play a prime role in identifying neoplasia and eliminating cancer cells. Over a decade, our understanding of immune system has grown tremendously and has advanced with immunotherapies for various diseases.
The possibility of applying immunotherapy to treat diseases has attracted an enormous amount of scientific, clinical, and commercial interest. Translating this potential into reality will require collaboration between scientists working on optimization of genome editing techniques, and drug delivery. With the aim of nurturing this collaboration and student learning objectives, the College of Pharmacy at the University of Nebraska Medical Center (UNMC) is organizing the 5th Annual Biopharmaceutical Research & Development Symposium on September 5-6, 2018. This two-day symposium will include speakers from each of these distinct scientific communities. At this symposium, we will be to invite leaders in the field of immunotherapy, genome editing, drug delivery, polymer chemistry, biophysics, clinicians, bioinformatics, and genetics to discuss the pros and cons of immunotherapy. Through talks, poster session, and panel of discussion, this meeting will help identify the scientific, clinical and regulatory hurdles that remain to be overcome. We will invite speakers from academia, industry, and regulatory affairs to provide a multidisciplinary forum for scientists to educate, interact and discuss recent advances and challenges related to immunotherapy and genome editing. In addition, two post-doctoral and two pre-doctoral graduates will be selected to give an oral presentation. Pre/Post-doctoral graduates will be encouraged to make poster presentation. This symposium will provide a unique opportunity to the faculty, post-docs, graduate students, women, minorities, and individuals with disabilities of local and national universities to have discussions with scientists from industries on the topics of mutual interest.
Goals and Objectives
This symposium will highlight current state of the art and practices in pharmaceutical industries in the discovery and development of immunotherapy for human dieses. The following issues will be discussed at this symposium:
- Provide the latest update on nanomedicines, immunotherapy, and genome engineering-based therapeutics.
- Discuss the critical issues regarding the delivery of therapeutics.
- How to establish successful industry-academia collaboration
- How to translate laboratory research into real industry level.
Who should attend?
Scientists in both academia and industry who desire to learn the current issues and perspectives in the practice of “Nanomedicine, Immunotherapy, and Genome-Engineering” from scientific, industrial and regulatory perspectives.
Reports of original data should include an abstract of no more than 500 words including background, methods, results and conclusions. Figures and illustrations are not allowed. As font, please use Arial, size 11. Abstracts chosen for poster presentation at the symposium must be prepared in advance on a poster board, 8 feet wide by 4 feet high (2.44 x 1.22 meters) (Landscape Orientation).
- Joyce Solheim (UNMC)
- Maneesh Jain (UNMC)
- Jennifer L. Guerriero (Harvard Medical School)
- Lily Yang (Emory University School of Medicine)
- Adam W. Barb (Iowa State University)
- Wendy Lynn Picking (Kansas University)
- Mingnan Chen (University of Utah)
- Sunil Krishnan (MD Anderson Cancer Center)
- Taosheng Chen (St Jude’s Children Research Hospital)
- Kristy Ainslie (University of North Carolina)
- Bob Kane (Baylor University Department of Chemistry and Biochemistry)
- Donald L. Durden (University of California San Diego)
Ram I. Mahato, Ph.D., Professor and Chairman of the Department of Pharmaceutical Sciences at UNMC
David Oupicky, Ph.D., Professor and Center for Drug Delivery and Nanomedicine, Co-Director at UNMC
Martin Conda-Sheridan, Ph.D., Assistant Professor, Department of Pharmaceutical Sciences at UNMC